Resistance Training, Detraining, and Retraining Study 2024 (TraDeRe2024)
Launched by UNIVERSITY OF JYVASKYLA · Aug 25, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Resistance Training, Detraining, and Retraining Study 2024 (TraDeRe2024) is a research project that aims to understand how different people respond to resistance training, which is exercise aimed at building muscle strength. The study will look at why some individuals see more muscle growth than others after following a resistance training program. Researchers want to know if the way someone's muscles grow after one training session can predict how they will respond to another training session later on. They will also explore whether individuals who typically see less muscle growth can benefit from doing more training.
The study is currently looking for healthy adults aged 18 to 50 who have previously participated in an earlier phase of the trial. Participants will take part in a 12-week supervised resistance training program and will undergo various assessments, such as muscle tests and collecting samples of urine, saliva, and blood to measure muscle growth and breakdown. Throughout the study, participants will also fill out questionnaires about their lifestyle and undergo multiple tests to check their muscle size and strength. This study is important for helping us understand how to improve exercise effectiveness for everyone, especially those who may not respond as well to traditional training methods.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age 18-50
- • healthy (e.g., no diagnosed type 2 diabetes, cardiovascular disease, musculoskeletal disorders, etc.)
- • prior participation in intervention I (NCT05874986)
- Exclusion Criteria:
- • medication affecting the cardiovascular system or metabolism
- • metabolic, musculoskeletal, cardiovascular, or other diseases or disorders which may preclude the ability to perform exercise training and testing
About University Of Jyvaskyla
The University of Jyväskylä is a leading research institution in Finland, renowned for its commitment to advancing knowledge through innovative scientific inquiry and interdisciplinary collaboration. With a strong emphasis on health sciences, the university conducts cutting-edge clinical trials aimed at improving patient outcomes and enhancing public health. Its research initiatives are supported by state-of-the-art facilities and a team of experienced professionals dedicated to ethical research practices and the translation of scientific findings into real-world applications. The university fosters an environment of academic excellence and is dedicated to contributing to the global body of medical knowledge through rigorous research and development.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jyväskylä, Central Finland, Finland
Patients applied
Trial Officials
Juha P Ahtiainen, Assoc.Prof.
Principal Investigator
University of Jyväskylä, Faculty of Sport and Health Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported